ANKTIVA ® Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA product ImmunityBio’s 400,000 square foot GMP fill-finish facility in ...
Dunkirk’s state-of-the-art facility is expected to play a significant role in the production of a new cancer-fighting drug developed by ImmunityBio Inc. On Tuesday, the company announced in a news ...
ImmunityBio Chief Executive Officer Richard Adcock acknowledges the frustration with how long it’s taken getting the Dunkirk ...
Stocktwits on MSN
IBRX stock climbs overnight: ImmunityBio declares 'all systems go' for Dunkirk Anktiva manufacturing push
CEO Richard Adcock said the long-delayed Dunkirk manufacturing site is now “all systems go” after a unanimous resolution at a CCIDA board meeting. ・The Dunkirk facility is expected to serve as a key U ...
DUNKIRK, N.Y. — ImmunityBio has filed a WARN notice with the New York state Department of Labor for two layoffs at its plant in Dunkirk. According to the notice, the California-based biopharmaceutical ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min ImmunityBio plans to use the ...
As it continues construction, ImmunityBio noted in a quarterly regulatory filing that it believes governmental funding will assist in funding a portion of the further build-out in Dunkirk. As of March ...
Over 400,000 square foot, state-of-the-art, finish-fill and lyophilization facility enables one billion doses of RNA and adjuvant vaccine production Newly constructed Current Good Manufacturing ...
A long-stalled pharmaceutical manufacturing project in Dunkirk may finally be moving toward a restart, with a revised agreement setting new financial terms, deadlines, and hiring expectations for ...
ImmunityBio has secured final local approval to restart its long-delayed Dunkirk, New York manufacturing facility, set to become a key U.S. hub for its cancer immunotherapy Anktiva. The project ...
It’s been an up-and-down several years at a state-funded, $200 million drug manufacturing plant in Dunkirk, a facility that – to date – still has not actually manufactured a drug.
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX) announced today that the drug substance (DS) has been completed and successfully qualified for “fill finish” (filling vials and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results